Cargando…

The potency and synergy of plant‐made monoclonal antibodies against the BA.5 variant of SARS‐CoV‐2

Detalles Bibliográficos
Autores principales:	Sun, Haiyan, Jugler, Collin, Nguyen, Katherine, Steinkellner, Herta, Chen, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877843/ https://www.ncbi.nlm.nih.gov/pubmed/36519524 http://dx.doi.org/10.1111/pbi.13980

Ejemplares similares

A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV‐2 Omicron variant
por: Jugler, Collin, et al.
Publicado: (2022)

A Monoclonal Antibody Produced in Glycoengineered Plants Potently Neutralizes Monkeypox Virus
por: Esqueda, Adrian, et al.
Publicado: (2023)

Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component
por: Jugler, Collin, et al.
Publicado: (2022)

A Dual-Approach Strategy to Optimize the Safety and Efficacy of Anti-Zika Virus Monoclonal Antibody Therapeutics
por: Sun, Haiyan, et al.
Publicado: (2023)

SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody
por: Jugler, Collin, et al.
Publicado: (2021)

Humanization and expression of IgG and IgM antibodies in plants as potential diagnostic reagents for Valley Fever
por: Jugler, Collin, et al.
Publicado: (2022)

Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection
por: Yang, Ming, et al.
Publicado: (2023)

Hydrophobin-Protein A Fusion Protein Produced in Plants Efficiently Purified an Anti-West Nile Virus Monoclonal Antibody from Plant Extracts via Aqueous Two-Phase Separation
por: Jugler, Collin, et al.
Publicado: (2020)

In vitro and in vivo efficacy of anti‐chikungunya virus monoclonal antibodies produced in wild‐type and glycoengineered Nicotiana benthamiana plants
por: Hurtado, Jonathan, et al.
Publicado: (2019)

Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
por: Zheng, Qianqian, et al.
Publicado: (2022)

Rapid High Yield Production of Different Glycoforms of Ebola Virus Monoclonal Antibody
por: Castilho, Alexandra, et al.
Publicado: (2011)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use
por: Grandits, Melanie, et al.
Publicado: (2023)

Plant glyco-biotechnology on the way to synthetic biology
por: Loos, Andreas, et al.
Publicado: (2014)

Advanced Plant-Based Glycan Engineering
por: Montero-Morales, Laura, et al.
Publicado: (2018)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Plant-based biopharmaceutical engineering
por: Eidenberger, Lukas, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Generation and Analysis of Novel Plant-Derived Antibody-Based Therapeutic Molecules against West Nile Virus
por: He, Junyun, et al.
Publicado: (2014)

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies
por: Stein, AM, et al.
Publicado: (2017)

Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab
por: Fujita, Shigeru, et al.
Publicado: (2022)

Fc-optimized monoclonal antibodies show superior efficacy
por: Flemming, Alexandra
Publicado: (2021)

Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron
por: Zhou, Bing, et al.
Publicado: (2022)

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
por: Makdasi, Efi, et al.
Publicado: (2021)

Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3
por: Tsekoa, Tsepo Lebiletsa, et al.
Publicado: (2016)

Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
por: Carlin, Aaron F, et al.
Publicado: (2023)

Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency
por: Cai, Cindy X., et al.
Publicado: (2022)

Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
por: Bruel, Timothée, et al.
Publicado: (2022)

Improvement of Anti-CD36 Antibody Detection via Monoclonal Antibody Immobilization of Platelet Antigens Assay by Using Selected Monoclonal Antibodies
por: Xu, Xiuzhang, et al.
Publicado: (2023)

Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones
por: Miglietta, Riccardo, et al.
Publicado: (2014)

Comparative analysis of plant transient expression vectors for targeted N-glycosylation
por: Eidenberger, Lukas, et al.
Publicado: (2022)

Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants
por: Pogue, Jason M, et al.
Publicado: (2021)

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants
por: ter Meulen, Jan, et al.
Publicado: (2006)

Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus
por: Sun, Haiyan, et al.
Publicado: (2023)

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
por: Kwak, Yee Gyung, et al.
Publicado: (2022)

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors: Fc-mediated avidity enhances the potency of an anti-TLR4 antibody
por: Loyau, Jérémy, et al.
Publicado: (2014)

Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies
por: Bennett, Lindsay D., et al.
Publicado: (2018)

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
por: Agadjanyan, Michael G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_326skhl6pik5qv9hm5b1brh24e